Unlock special prices! Log in or register to reveal exclusive offers.
01aaa_7839-20-1-jpg

SARS-CoV-2 lso1 Lin B.1.526_2021 lota (NY Wadsworth-21025952-01/2021) Culture Fluid (UV Inactivated)

The prices will be displayed on the checkout.

SARS-Related Coronavirus 2 Lineage B.1.526_2021; lota Variant (Isolate: USA/NY-Wadsworth-21025952-01/2021 Isolate 1) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus.
SARS-CoV-2 isolate USA/NY-Wadsworth-21025952-01/2021 Isolate 1 was collected in January 2021 in New York, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data),SARS-CoV-2, isolate USA/NY-Wadsworth-21025952-01/2021 Isolate 1 is assigned lineage B.1.526. It was labelled as lota variant by the World Health Organization (WHO). The complete genome of SARS-CoV-2, isolate USA/NY-Wadsworth-21025952-01/2021 Isolate 1 has been sequenced (GISAID: EPI_ISL_1016233).
Each frozen aliquot contains 1 mL of UV inactivated, clarified viral culture fluid. The pre-inactivation titer was determined from an infectious aliquot.
Viral inactivation is verified after UV inactivation by the absence of viral growth in tissue culture-based infectivity assays.

UV Inactivated viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage.
These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

For BSL-2 or BSL-3 compliant labs only. / -20° C.
Product Insert.pdf

Material Safety Data Sheet.pdf

FacebookTwitterLinkedin

Additional Information

Product Code

Origin

USA

BTN - HC

Organism

,

Size

KGS

Shipping Conditions

0
    Your Cart
    Your cart is emptyReturn to Shop

    Unlock special prices!
    Log in or register to reveal exclusive offers.